What is Vaxcyte?
Headquartered in San Carlos, California, Vaxcyte is dedicated to enhancing global health through the creation of superior and novel vaccines. The company's focus lies in preventing and treating some of the world's most common and deadly infectious diseases. Vaxcyte's approach involves leveraging advanced vaccine technology to address unmet medical needs, positioning it as a key player in the biotechnology and public health sectors. The company's commitment to scientific innovation drives its mission to deliver impactful health solutions.
How much funding has Vaxcyte raised?
Vaxcyte has raised a total of $1.1B across 7 funding rounds:
Series A
$22M
Series B
$60M
Other Financing Round
$4M
Series C
$85M
Series D
$110M
Stock Offering
$100M
Share Placement
$750M
Series A (2015): $22M with participation from Longitude Capital, Roche, Abingworth, and CTI Life Sciences Fund
Series B (2017): $60M led by Frazier Healthcare Partners, Longitude Capital, Roche, CTI Life Sciences Fund, Pivotal Bioventure Partners, and Abingworth
Other Financing Round (2017): $4M supported by Abingworth, Longitude Capital, Roche, and CTI Life Sciences Fund
Series C (2018): $85M, investors not publicly disclosed
Series D (2020): $110M backed by Texas Pacific Group, Longitude Capital, Roche, CTI Life Sciences, RA Capital Management , LLC, Abingworth LLP, Pivotal Bioventure Partners, Medixc, Janus Henderson Group, Foresite Capital, and Frazier Health Care Partners
Stock Issuance/Offering (2022): $100M, investors not publicly disclosed
Share Placement (2024): $750M, investors not publicly disclosed
Key Investors in Vaxcyte
Frazier Healthcare Partners
Frazier Healthcare Partners is a venture capital firm specializing in the healthcare sector, investing in companies that aim to improve patient care and scale innovative solutions.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, providing sector expertise and capital to help innovators scale.
Roche
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions and personalized medicine.
What's next for Vaxcyte?
With substantial backing, Vaxcyte is poised for accelerated growth and the advancement of its vaccine pipeline. The recent major strategic investment suggests a focus on scaling operations, expanding research and development capabilities, and potentially preparing for later-stage clinical trials or commercialization efforts. The company's continued access to capital from prominent investors signals confidence in its scientific approach and market potential, paving the way for future breakthroughs in infectious disease prevention.
See full Vaxcyte company page
